Key Points Portolan Capital increased its Cellebrite position by 1,407,818 shares, worth an estimated $28.65 million. The transaction equates to approximately 1.20% of 13F reportable assets under management (AUM). Portolan's post-trade Cellebrite stake: 2,419,662 shares valued at $44.84 million. Cellebrite represents approximately 2.43% of AUM and is the fund's 10th-largest holding. These 10 stocks could mint the next wave of millionaires › Portolan Capital Management, LLC disclosed a significa ...